Biomarker-Guided therapy aims to wipe out esophageal cancer before surgery
NCT ID NCT06601309
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 21 times
Summary
This study tests a new approach for people with a type of esophageal cancer that can be surgically removed. Before surgery, patients receive a treatment plan tailored to their tumor's CPS score, a measure of a protein called PD-L1. The goal is to see if this personalized pre-surgery treatment can completely eliminate the cancer, making the surgery more effective. About 90 adults with stage II or III esophageal squamous cell carcinoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.